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Complete vascular isolation for in situ perfusion of organs or body
parts provides interesting opportunities for cancer treatment.
When properly performed, i.e. when leakage to the systemic circu-
lation is avoided, delivery of anticancer drugs via an isolated
circuit may have the obvious advantage that compounds and/or
dosages can be used that would cause fatal complications if deliv-
ered systemically. In the treatment of irresectable hepatic metas-
tases derived from colorectal cancer – a tumour type known to be
quite resistant to systemic anticancer treatment – isolated hepatic
perfusion (IHP) was already attempted clinically in the 1980s
(Aigner et al, 1988). It was anticipated that by this approach a
larger array of cytotoxic compounds could be tested, especially
drugs with a steep dose–response relationship and with a higher
toxicity to tumour cells than to surrounding liver tissue. IHP has
been tested with drugs like melphalan (L-PAM) (Hafstrom et al,
1994), mitomycin C (MMC) (Marinelli et al, 1996), cisplatin
(Hafstrom et al, 1994), 5-fluorouracil (Aigner et al, 1988) and
tumour necrosis factor (TNF) (Borel Rinkes et al, 1997; Alexander
et al, 1998). Recently, several clinical trials (Alexander et al, 1998;
Oldhafer et al, 1998) have been started, exploring the efficacy of
IHP with TNF and L-PAM under mild hyperthermic conditions to
treat unresectable cancers confined to the liver (most of colorectal
origin).
To date the number of drugs considered for IHP studies is still
very limited, as these agents need to be effective after a single
exposure (lasting no longer than the perfusion duration believed to
be maximally obtainable without complications). Alkylating agents
like MMC and L-PAM are effective against colorectal cancer after
relatively short exposure times (Marinelli et al, 1991a, 1991b) and
it is believed that above a certain threshold concentration, a rela-
tively small increase in local drug concentration may result in a
dramatic increase in tumour cell kill (Garcia et al, 1988). A high
response rate (45%) has been reported for high dosed L-PAM in
combination with autologous bone marrow transplantation as treat-
ment for metastatic colon carcinoma (Leff et al, 1986). Whereas in
the latter study no serious hepatotoxicity was observed, veno-
occlusive disease (VOD) of the liver has been a recurrent problem
after IHP with MMC (Marinelli et al, 1996; Oldhaffer et al, 1998).
Moreover, comparing in a rat model for colorectal cancer hepatic
metastases IHP with MMC, 5-fluorouracil or L-PAM, we found
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Summary A phase I dose-escalation study was performed to determine whether isolated hepatic perfusion (IHP) with melphalan (L-PAM)
allows exposure of the liver to much higher drug concentrations than clinically achievable after systemic administration and leads to higher
tumour concentrations of L-PAM. Twenty-four patients with colorectal cancer confined to the liver were treated with L-PAM dosages escalating
from 0.5 to 4.0 mg kg–1. During all IHP procedures, leakage of perfusate was monitored. Duration of IHP was aimed at 60 min, but was
shortened in eight cases as a result of leakage from the isolated circuit. From these, three patients developed WHO grade 3–4 leukopenia
and two patients died due to sepsis. A reversible elevation of liver enzymes and bilirubin was seen in the majority of patients. Only one patient
was treated with 4.0 mg kg–1 L-PAM, who died 8 days after IHP as a result of multiple-organ failure. A statistically significant correlation was
found between the dose of L-PAM, peak L-PAM concentrations in perfusate (R = 0.86, P ≤ 0.001), perfusate area under the concentration-
time curve (AUC; R = 0.82, P < 0.001), tumour tissue concentrations of L-PAM (R = 0.83, P = 0.011) and patient survival (R = 0.52, P = 0.02).
The peak L-PAM concentration and AUC of L-PAM in perfusate at dose level 3.0 mg kg–1 (n = 5) were respectively 35- and 13-fold higher than
in the systemic circulation, and respectively 30- and 5-fold higher than reported for high dose oral L-PAM (80–157 mg m–2) and autologous
bone marrow transplantation. Median survival after IHP (n = 21) was 19 months and the overall response rate was 29% (17 assessable
patients; one complete and four partial remissions). Thus, the maximally tolerated dose of L-PAM delivered via IHP is approximately 
3.0 mg kg–1, leading to high L-PAM concentrations at the target side. Because of the complexity of this treatment modality, IHP has at
present no place in routine clinical practice. © 2000 Cancer Research Campaign
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rats (Marinelli et al, 1991a, 1991b). These findings formed a
sound rationale to start a phase I dose-finding study of IHP with L-
PAM, which was performed during 1991–1994 in 24 patients.
Because no relevant data had been published before on the
pharmacokinetics of L-PAM in IHP setting, we sampled from all
patients samples from the systemic circulation and isolated circuit,
and, when possible, tumour and/or liver biopsies to determine L-
PAM concentrations.
PATIENTS AND METHODS
Patient eligibility
Between May 1991 and March 1994, 24 patients with colorectal
cancer confined to the liver were treated with a 60-min IHP using
L-PAM dosages (Wellcome Pharmaceuticals B.V., Utrecht, The
Netherlands) escalating from 0.5 to 4.0mg kg–1. This study was
approved by the medical ethical committee of the Leiden
University Medical Center, and informed consent was obtained
from all patients. Selection criteria for IHP treatment were that no
primary colorectal tumour was left and that metastases were
confined to the liver and totally irresectable. Therefore, all patients
were analysed using abdominal/chest computerized tomography
(CT) and magnetic resonance imaging (MRI) scans. Eligibility
criteria included a WHO performance status of 0 or 1, a leucocyte
count ³3.0 ´109 l–1, a platelet count ³100.0 ´109 l–1, a serum
creatinine level <135 mmol l–1, a bilirubin level <17 mmol l–1, an
albumin level >40g l–1  and with no coagulation disorders. Patients
were excluded who had more than 75% hepatic replacement by
tumour tissue or evidence of malignant ascites.
IHP technique
The IHP technique with intra-caval double lumen shunt was used
for the first 19 patients as previously described (Marinelli et al,
1996). Through a transversal abdominal incision the liver was first
mobilized from the diaphragm and identifiable diaphragm veins
were ligated. The pericardium was opened and the caval vein was
dissected. After heparinization of the blood, the intrahepatic caval
vein was cannulated with a specially designed double lumen
catheter (Braun Melsungen, Germany). The inner lumen of this
catheter allowed undisturbed blood flow to the right atrium of 
the heart, whereas the outer lumen served as a reservoir from which
the hepatic venous outflow returned to a Cobe VPCML oxygenator
(Cobe Cardiovascular, Inc, Arvada, CO, USA). The priming
volume of the IHP system consisted of 1200ml Gelofusine (Vifor
Medical SA, Sempach, Switzerland) containing 2500 IE heparin.
The mesenteric venous blood was drained to the inner lumen of 
the double lumen catheter by a temporary porto-caval shunt, which
was established by cannulating the distal portal vein and
connecting the catheter with the corresponding nozzle of the double
lumen catheter. The two inflow limbs of the isolated circuit were
both connected to two independent oxygenators (Custom-made
liver perfusion tubing pack, Cobe Laboratories, Ltd, Gloucester,
UK) and roller pumps (Cobe/Stöckert, model 10–30–00, Munich,
Germany). One catheter entered into the portal vein and another
through the gastroduodenal artery into the common hepatic artery.
To isolate the hepatic circuit, tourniquets were secured around the
caval vein above and below the incision, above the renal veins and
within the pericardium. The celiac axis and the common bile duct
were clamped. Throughout the perfusion period, the perfusate was
kept at 37–38°C.
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Figure 1Isolated hepatic perfusion circuit with extra-corporeal veno-venous bypassFor the last five patients of this study, we used a different IHP
technique (Vahrmeijer et al, 1996) with extracorporeal veno-
venous bypass, supported by a Biomedicus centrifugal pump
(Medtronic Bio-Medicus, Inc., Eden Prairie, MN, USA) (Figure
1). The right femoral vein was cannulated as well as the portal vein
(proximal of the clamp) and connected to the right axillary vein
(Gott, 7 mm cannula, Argyle, Sherwood Medial, St Louis, MO,
USA). The system was primed with 700 ml saline (0.9%). The
blood flow through the veno-venous bypass was approximately 
21 min–1. Systemic hypothermia throughout the perfusion period
was prevented by the application of a heat-exchanger (Avecor
Cardiovascular, Inc., Plymouth, MN, USA) which was placed
between the tubing of the veno-venous bypass. To isolate the liver,
the hepatic artery and portal vein were cannulated as described
above. In contrast to the above-described technique, the caval vein
was clamped above the right renal vein and below the diaphragm.
The intrahepatic caval vein was cannulated (Polystan 36 French,
straight, A/S, Värlöse, Denmark) to allow undisturbed blood flow
from the hepatic veins via the caval vein to the heart–lung
machine. After the 1-h perfusion period, the liver was flushed
during approximately 10 min with 3 l Gelofusine. Thereafter, all
catheters and clamps were removed and all incisions were closed.
To prevent possible post-operative L-PAM induced cholecystitis, a
cholecystectomy was performed.
Leakage of perfusate into the systemic circulation was moni-
tored by adding 99mTc-pertechnetate (99mTc) to the isolated circuit
and subsequent measurement of the level of radioactivity in both
the systemic and isolated circuit as previously described (Runia et
al, 1987; Marinelli et al, 1996). If no leakage was detected, L-PAM
(freshly prepared solution) was administrated as a bolus to the
isolated circuit. In case of unacceptable leakage (e.g. above 10% at
the highest L-PAM dose level) during the perfusion period, the
procedure was immediately stopped and the liver was flushed as
mentioned above at the IHP technique.
Post-operative care
All patients were monitored in the intensive care unit for at least 
1 day after IHP. Liver and kidney function tests (ALAT, ASAT,
bilirubin, alkaline phosphatase, g-GT, LDH, creatinine, ureum),
number of platelets and white blood cell count were measured
frequently. Toxicity was determined according to WHO recom-
mendations. Patients received G-CSF (Filgrastim/Neupogen®,
Amgen B.V., Breda, The Netherlands) in case of grade 3–4
leukopenia and routinely when treated with 3.0 mg kg–1 L-PAM
from 1 day after IHP until after the nadir.
L-PAM pharmacokinetics
Heparinized samples for L-PAM measurements were taken at
regular intervals from the perfusion medium and from the systemic
circulation. Samples were centrifuged for 10 min at 750 g, and the
supernatant was stored at –80°C until analysis. In 12 cases, tumour
and/or liver biopsies were taken within 30 min after IHP treatment,
and immediately frozen in liquid nitrogen. All samples were
analysed for L-PAM concentrations by an HPLC assay (Chang et
al, 1978). The areas under the concentration-time curves (AUC)
were calculated with the trapezoidal rule. The amount of L-PAM
in tissue samples was expressed as mg g–1 wet tissue.
Treatment evaluation
Objective tumour responses were obtained by follow-up CT scans
of the liver approximately 3 months after IHP treatment. Four
patients were excluded because either no post-operative CT scans
were available or tumour measurements were in view of the large
amount of metastases unrealistic. A complete response (CR) was
defined as a total disappearance of all lesions; a partial remission
(PR) was defined as at least a 50% reduction in tumour size (the
sum of the product of the perpendicular diameters of all measur-
able lesions); a stable disease (SD) was defined as less than 50%
tumour size regression or less than 25% progression, and progres-
sive disease (PD) was defined as more than 25% progression.
Moreover, CEA levels were measured before and after IHP treat-
ment.
Statistics
All data were analysed using SPSS (version 9.0) software and
presented as mean ± s.d. For all statistical analyses, a P-value 
< 0.05 was considered statistically significant. Correlation coeffi-
cients were calculated using the non-parametric Spearman’s test.
RESULTS
Patient characteristics and IHP technique
Half of the patients treated in this study were staged Dukes’ D at
time of primary tumour resection. Mean age of treated patients was
53 years (range 36–64), the majority (15) being male. Only three
patients previously had received chemotherapy.
Based on the L-PAM dose level, a maximum percentage of
leakage (e.g. 10% 99mTc leakage at dose level 3.0 mg kg–1) was 
set beforehand, above which the perfusion should be terminated.
IHP for colorectal cancer hepatic metastases 1541
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Table 1 IHP parameters
Parameter With intra-caval shunt With veno-venous bypass
Mean ± s.d. Range Mean ± s.d. Range
Flow rate (ml min–1)
Hepatic artery 403 ± 160 190–800 502 ± 86 400–621
Portal vein 492 ± 148 210–800 393 ± 66 315–460
Total 895 ± 146 595–1210 895 ± 145 715–1051
Pressure, mmHg
Hepatic artery 132 ± 36 80–200 164 ± 38 120–207
Portal vein 36 ± 12 10–70 37 ± 9 30–48
Leakage (%) 15 ± 14 0–41 7 ± 5 2–15
Duration of perfusion, min 51 ± 13 25–60 48 ± 16 30–601542 AL Vahrmeijer et al
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1Duration of IHP was aimed at 60 min, but as a result of leakage
from the isolated circuit to the systemic circulation, perfusion
duration was prematurely stopped in eight cases. Based on this
relatively high incidence of systemic leakage, we decided after 19
patients to change the IHP procedure, applying an external circuit
to bypass the liver (Figure 1). In the next five patients, the perfu-
sion procedure was stopped earlier in two cases. The present series
is too small to derive definite conclusions whether leakage can be
better controlled by applying the IHP technique with veno-venous
bypass. However, it was recently reported that by using a similar
IHP technique, only in two of 34 treated patients systemic leakage
of perfusate was detected (Alexander et al, 1998). Perfusion para-
meters are listed in Table 1. Total mean perfusion flow did not
differ significantly among the two different IHP techniques
applied (being 895 ml min–1 in both cases), and also the mean of all
other perfusion parameters did not differ significantly. Therefore,
we considered all patients as one group.
The surgical procedure (including the 1-h perfusion period) took
approximately 5 h (range 4–7.5 h). Blood loss during the operation
was considerable and ranged from 1.5 to 10 l. All patients stayed at
least 1 day (standard protocol) in the intensive care unit, with a mean
duration of 4 days (range 1–36 days). Mean hospital stay was 17
days (range 8–53 days). Of all patients treated, 50% were discharged
from the hospital within 14 days after the perfusion. Three patients
died as a result of the IHP treatment (14% mortality rate).
L-PAM pharmacokinetics
Data on individual L-PAM pharmacokinetics are listed in Table 2.
From all patients treated by IHP, L-PAM concentrations were
measured in both the isolated circuit and the systemic circulation
and the AUC was calculated. The AUC in the perfusate reflects the
L-PAM exposure to the liver and metastases. A statistically signifi-
cant correlation was found between the L-PAM dose and the peak
concentration (R = 0.86, P < 0.001) and the AUC (R = 0.82, 
P < 0.001) of L-PAM in perfusate respectively. Figure 2 shows 
two examples of the L-PAM concentration in the perfusate at two
dose levels (respectively 1.5 mg kg–1 and 3.0 mg kg–1): a twofold
increase in L-PAM dose translated into a similar increase in peak
L-PAM concentration in perfusate as measured 5 min after addi-
tion of L-PAM. Based on the estimated peak L-PAM concentration
in perfusate, a biphasic decline in L-PAM concentrations was
found in perfusate, indicating a rapid uptake phase followed by a
much slower elimination phase.
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Figure 2 Concentration of L-PAM in perfusate during the one-hour
perfusion period after addition of either 1.5 mg kg–1 (l) or 3.0 mg kg–1 (n) 
L-PAM to the isolated circuit. The calculated L-PAM peak concentration is
indicated
Figure 3 Concentration of L-PAM (n) in the systemic circulation during and
after the IHP procedure after addition of 3.0 mg kg–1 L-PAM to the isolated
circuit. Moreover, a typical pattern of the signal of 99mTc labelled red blood
cells (l) in the systemic circulation is shown. A peak 99mTc level of 120
counts in the systemic circulation resembles a calculated leakage percentage
of approximately 4–5%
Table 3 Toxicity according to WHO criteria
Parameter Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
No. % No. % No. % No. % No. %
Leucocyte 15 63 2 8 2 8 1 4 3 13
Platelets 14 59 3 12 1 4 2 8 4 17
Creatinine 20 80 2 8 2 8 1 4 0 0
ALAT 14 61 6 26 2 9 0 0 1 4
A S A T 2 0 8 72 90 00 01 4
Bilirubin 10 44 5 22 4 17 3 13 1 4
Hepatotoxicity parameters (ALAT, ASAT, bilirubin) were scored from day 7 after perfusion. For hepatotoxicity, 23 patients
were evaluated because one patient died within 7 days after IHP.The mean peak concentration and AUC of L-PAM in perfusate
in patients treated at the highest tolerable dose level (3.0 mg kg–1)
were 38.6 ± 10.8 mg ml–1 and 16.6 ± 5.5 h mg ml–1 respectively,
whereas the mean systemic peak plasma concentration and AUC
were 1.1 ± 0.5 mg ml–1 and 1.3 ± 0.8 h mg ml–1. These data demon-
strate that at the target side, the peak L-PAM concentration and the
AUC L-PAM were respectively 35- and 13-fold higher than in the
systemic circulation, and clearly indicate that a complete vascular
isolation of the liver can be obtained for a prolonged period of
time.
The peak L-PAM concentration in the systemic circulation was
always observed after termination of the IHP procedure. In the
majority of cases almost no systemic leakage of L-PAM was
observed during the IHP treatment; a typical case is shown in
Figure 3. This pattern corresponds with the level of radioactivity in
the systemic circulation: after the washout period when the clamps
were removed from the caval vein, approximately 4–5% of the
total dose 99mTc, was re-distributed into the systemic circulation
(Figure 3). All 99mTc is supposed to be bound to red blood cells
(Runia et al, 1987). Because of the identical re-distribution pattern
of L-PAM and the 99mTc-labelled red blood cells, this residual L-
PAM probably originates from vessels not sufficiently flushed
after the perfusion period.
It was possible to collect tumour and liver tissue biopsies from a
limited number of patients (n = 8) treated at various L-PAM
dosages. The amount of L-PAM detected by HPLC in tumour and
liver tissue ranged from 0 to 20.8 and 1.4–15.7 mg g–1 respectively.
A statistically significant correlation was found between the
amount of L-PAM in tumour and liver tissue and the dose level
(tumour: R = 0.83; P = 0.011, liver: R = 0.65; P = 0.022) or AUC
perfusate (tumour: R = 0.76; P = 0.03, liver: R = 0.71; P = 0.01) of
L-PAM.
Toxicity of L-PAM
With respect to bone marrow-related toxicity, four patients devel-
oped grade 3–4 leukopenia and six patients developed grade 3–4
thrombocytopenia (Table 3). Most patients had only a small drop
in leukocytes and the nadir (mean 4.8 ± 2.8 109 l–1, range 0.1–9.3)
was usually observed approximately 8–9 days after IHP. A signifi-
cant correlation was found between the nadir in leukocytes and the
dose level of L-PAM (R = –0.47, P = 0.024). Two of the three
patients who developed a grade 4 leukopenia, had the two highest
systemic L-PAM AUC values, making it likely that L-PAM was
responsible for the observed bone marrow toxicity. One of these
two patients died 11 days after IHP as a result of sepsis, which was
probably indirectly caused by massive systemic leakage (41%)
occurring shortly before termination of isolation. In this patient,
who was treated with 250 mg total dose L-PAM, a concentration
of 4.5 mg ml–1 L-PAM was measured in the systemic circulation
(being the highest concentration measured in our patient popula-
tion). The patient who developed a grade 3 leukopenia died 5 days
after the IHP treatment as a result of toxic shock. The observed
bone marrow toxicity might be related to systemic L-PAM leakage
because in this patient also a high systemic L-PAM concentration
of 2.9 mg ml–1 was measured.
The only patient who was treated with 4.0 mg kg–1 L-PAM
developed a grade 4 leukopenia shortly after IHP. No high
systemic L-PAM concentrations were measured (Table 2), which
was in accordance with 99mTc measurements during perfusion,
indicating no systemic leakage. This patient died 8 days after the
IHP procedure, showing acute liver and kidney failure, adult respi-
ratory distress syndrome and coagulation disorders. This patient
had approximately 60% of the liver involved with tumour tissue,
which most likely was an additional risk factor. At autopsy, all
tumour tissue with surrounding liver tissue was found to be
necrotic. Therefore, the observed bone marrow toxicity and devel-
opment of multiple-organ failure in this patient could be due to the
release of cytokines like TNF from the liver.
During the first 2 days after IHP, all patients had a minor to
marked increase in the serum level of bilirubin (mean 71 ± 76
mmol l–1, range 13–372), LDH (mean 3034 ± 4397 U l–1, range
190–17 600), ASAT (mean 466 ± 833 U l–1, range 23–3900) and
ALAT (mean 319 ± 337 U  l–1, range 22–1078), which returned to
normal within approximately 1 week after IHP (Figure 4). No
correlation was found between L-PAM perfusion parameters and
the peak level of bilirubin, LDH, ASAT and ALAT, indicating that
the observed hepatotoxicity during the first days post-IHP was
caused in part by the perfusion procedure itself, including the
physical and vascular manipulations of the liver. Therefore, as
recently suggested (Alexander et al, 1998), elevations in liver
enzymes and bilirubin beyond 7 days after the IHP procedure were
considered as L-PAM-related. Based on both bilirubin and liver
enzyme levels, grade 4 hepatotoxicity was observed only in the
patient who was treated with 4.0 mg kg–1 L-PAM. In the majority
of patients, grade 0 and 1 hepatotoxicity was observed (Table 3).
Tumour response and patient survival
In this series, 17 patients were evaluable for measurement of
tumour response and the overall response rate was 29% (Table 2:
one complete remission, four partial remissions, six stable diseases
and six progressive cases). All patients had a substantial decrease
in carcinoembryonic antigen (CEA) after IHP ranging from 21%
to normalization of the CEA level (CEA ≤ 3.0 mg ml–1), which was
observed in seven patients (Table 2). Patient survival after IHP
treatment ranged from 3.7 up to 85 months, but no correlation was
found between CEA decrease and survival duration. Median and
mean patient survival of the whole series (n = 21) after IHP were
19 and 27 months respectively, and 23 and 31 months respectively
after the diagnosis of liver metastases. A statistically significant
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Figure 4 The amount of serum ALAT (l) and ASAT (n) after the IHP
procedure with 3.0 mg kg–1 L-PAM. A typical case is showncorrelation was found between patient survival after IHP and dose
level of L-PAM (R = 0.52; P = 0.02) and perfusate AUC (R = 0.47;
P = 0.03) respectively.
DISCUSSION
In the present study we evaluated L-PAM dose-escalation by IHP
as treatment for patients with colorectal cancer metastases confined
to the liver. Our data demonstrate that increasing the L-PAM dose
resulted in a statistically significant increase in AUC and peak L-
PAM concentrations in perfusate as well as increased L-PAM
uptake by tumour tissue. Compared to isolated limb perfusion 
for melanoma, peak L-PAM concentrations, perfusate AUC and
tumour concentrations were in the same range (Klaase et al, 1994).
However, the mean perfusate peak L-PAM concentration and AUC
at the highest tolerable dose level (3.0 mg kg–1) were approximately
30- and fivefold higher respectively, than reported for high dose
(80–157 mg  m–2) oral L-PAM and bone marrow transplantation
(Choi et al, 1989; Boros et al, 1990). Therefore, IHP enabled expo-
sure of the liver and metastases to much higher L-PAM concentra-
tions than achievable after systemic administration.
IHP is a technically difficult way of drug delivery with
morbidity and mortality associated with the operative procedure.
A weak but statistically significant correlation was found between
the L-PAM dose level and the nadir in white blood cells after IHP.
It is noteworthy that no correlation was found between L-PAM
concentration parameters and liver enzyme disturbances, indi-
cating that the observed hepatotoxicity during the first days after
the IHP procedure was caused by the IHP procedure itself rather
than by high drug levels – with possible exception of the only
patient treated with 4.0 mg kg–1 who died at day 8 after IHP as a
result of multiple-organ failure. In retrospect, the sudden death of
this patient might be explained by the fact that his liver contained a
high tumour load. A similar finding was described by Hafstrom
and colleagues (Hafstrom et al, 1994), who treated patients by IHP
with L-PAM and cisplatin under hyperthermic conditions: from
the patients who had more than 50% of the liver occupied by
cancer, 25% died within 30 days after IHP due to multiple-organ
failure. We concluded from these toxicity data that a maximum
dose of L-PAM for delivery via IHP is approximately 3.0 mg kg–1.
In most clinical IHP studies, livers were perfused arbitrarily for
1 h. Pharmacokinetic analysis of L-PAM in perfusate showed a
biphasic decline and we demonstrated that after the initial uptake
phase (approximately 10–15 min), the inflow and outflow L-PAM
concentrations were similar (Vahrmeijer et al, 1996), indicating
that the liver removed little L-PAM after the initial uptake phase.
These pharmacokinetic data suggest that in case of L-PAM, perfu-
sion duration can be shortened to approximately 15–30 min.
At present, it is unclear to what extent the perfusate temperature,
perfusion flow rate and pressure in the hepatic artery influence
tumour L-PAM uptake. In our study the mean flow rate and
pressure in the hepatic artery inflow catheter were 502 ml min–1
and 164 mmHg respectively; in the aforementioned study by
Alexander and colleagues (Alexander et al, 1998), who used a
combination of 1.5 mg kg–1 L-PAM and 1.0 mg TNF, the pressure
was in the same range (159 mmHg) but the flow rate was substan-
tially higher (844 ml min–1). Notably, the reported overall response
rate in the latter study was higher than in our study (76% vs 29%).
The addition of TNF, or the higher perfusion flow rate in the
hepatic artery, or the fact that they used mild hyperthermia (central
hepatic temperature of 39.9°C), or combinations thereof might
contribute to this remarkable difference in response rate.
The present series is too small to derive definite conclusions
with respect to response parameters, but data suggest that
increasing the L-PAM dose translates into prolonged patient
survival. Overall median survival after IHP in our series was 19
months (n = 21) and this is comparable to data that we obtained
with mitomycin C (Marinelli et al, 1996). Although no adjuvant
systemic treatment was given, the majority of patients received
standard chemotherapy following progression. With respect to
patient survival, until now best results with other techniques have
been obtained with fluoropyrimidines delivered as a continuous
infusion into the hepatic artery. Reported median survival dura-
tions from phase II trials of hepatic artery infusion (HAI) of
fluoropyrimidines (in patients who complied with the same selec-
tion criteria as used for IHP studies) range from 12 to 26 months
(Kemeny et al, 1994, 1995; Vahrmeijer et al, 1995; Meta Analysis
Group in Cancer, 1996). As soon as survival data from ongoing
phase II IHP studies become available, comparisons can be made
with the large amount of data obtained in HAI studies.
In the present series, five patients were treated with 3.0 mg kg–1
L-PAM and mean survival of this subgroup was 42 months (range
13–70 months). Moreover, two out of four evaluable patients had a
partial tumour remission (Table 2). Based on these initial favourable
results, we started a phase II study of IHP with 200 mg total dose L-
PAM. A fixed total dose of 200 mg L-PAM was chosen because this
dose was well tolerated in the present study. Moreover, in the
ongoing phase II study all patients receive granulocyte colony-
stimulating factor (Filgrastim/Neupogen®) to protect against
leukopenia. Irrespective of the outcome of latter study, it is clear that
IHP would gain much wider interest if the whole procedure could be
simplified. In that context, several investigators have proposed less
invasive techniques based upon balloon catheterization (Curley et
al, 1994; Ravikumar et al, 1994; van Ijken et al, 1998).
In conclusion, IHP is technically feasible. The largest propor-
tion of L-PAM was taken up within the first 10–15 min after addi-
tion of L-PAM to the perfusate and within the dose range
evaluated, higher doses of L-PAM indeed lead to higher concentra-
tions of L-PAM in the liver metastases. Doses up to 3.0 mg kg–1
did not lead to VOD or other serious hepatotoxicities. The current
ongoing phase II study will provide detailed information on
response of liver metastases to this treatment modality and the
impact on patient survival. However, it should be re-emphasized
that IHP is still an experimental treatment modality with at present
no place in routine clinical practice. Therefore, progress should be
made to develop a simplified procedure, e.g. a totally percuta-
neously applicable IHP technique.
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